Raloxifene administration in premenopausal women with uterine leiomyomas: A pilot study

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 8, 2002, Pages 3603-3608

  Palomba, Stefano ^a,e   Orio Jr , Francesco ^b   Morelli, Michele ^b   Russo, Tiziana ^c   Pellicano, Massimiliano ^d   Zupi, Errico ^a   Lombardi, Gaetano ^b   Nappi, Carmine ^b   Panici, Pier Luigi Benedetti ^c   Zullo, Fulvio ^d  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIVITAMIN; PLACEBO; RALOXIFENE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PILOT STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TRANSVAGINAL ECHOGRAPHY; UTERUS BLEEDING; UTERUS MYOMA;

EID: 18544385926     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.8.8747     Document Type: Article

References (42)

1. Uterine fibroids
2. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas?
3. Reduction in the size of a uterine leiomyoma following discontinuation of an estrogen-progestin contraceptive
4. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata
5. Regression of uterine leiomyomata in response to the antiprogesterone RU 486
6. Clinical efficacy of anti-progesterone RU 486 in the treatment of endometriosis and uterine fibroids
7. Long-term treatment of leiomyomas with gestrinone
8. Gestrinone in the treatment of myomas
9. Short-term treatment of uterine fibromyomas with danazol
10. Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata
11. A conservative approach to the management of uterine leiomyoma: Pituitary desensibilization by a lutenizing hormone-releasing hormone analogue
12. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonist: The estrogen threshold hypothesis
13. GnRH agonists and add-back therapy: Is there a perfect combination?
14. Long-term medical therapy for leiomyomata uteri: A prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin "add-back" for 2 years
15. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: A prospective, randomized, double blind, placebo-controlled, crossover trial
16. A clinical trial on the effects of tibolone association with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata
17. Long term administration of tibolone plus gonadotropin-releasing hormone agonist for treatment of uterine leiomyomas: Effectiveness and effects on vasomotor symptoms, bone mass, and lipid profile
18. Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy
19. Effect of postmenopause on bone metabolism in women previously treated with gonadotropin-releasing hormone agonist plus tibolone
20. Inhibition of estrogen stimulated growth of uterine leiomyomas by selective estrogen receptor modulators
21. A pharmacological review of raloxifene
22. Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
23. Effects of raloxifene in a guinea pig model for leiomyomas
24. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma
25. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women
26. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women
27. Clinical effects of raloxifene hydrocloride in women
28. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
29. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
30. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
31. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium
32. Uterine effects of 3-years raloxifene therapy in postmenopausal women younger than age 60
33. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
34. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
35. Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids
36. Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation
37. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata - A pilot study
38. Estrogen receptor gene expression in human uterine leiomyomata
39. Comparative messenger ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyomas and healthy myometrium
40. Gonadotrophin releasing hormone (GnRH) receptor and steroid receptors in human uterine leiomyomas, myometrium and endometrium
41. Estrogen receptors (ERα/ERβ) in normal and pathological growth of the human myometrium: Pregnancy and leiomyomas
42. Reproductive endocrine and endometrial hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles